Persistent Depressive Disorder
A mild but long-term form of depression.
Dysthymia is defined as a low mood occurring for at least two years, along with at least two other symptoms of depression.
Examples of symptoms include lost interest in normal activities, hopelessness, low self-esteem, low appetite, low energy, sleep changes, and poor concentration.
Treatments include medications and talk therapy.
Cluster Number:
Wiki Number: PW161
Diagnosis: Persistent Depressive Disorder-Dysthymia
US Patients: 3-6% during lifetime
World Patients: 105 Mil per year (1.5% of the population)
Sex Ratio:
Age Onset: 21, before 21 called “early onset”
Brain Area: In women, the corpus callosum and frontal lobes differ from normal; the amygdala, insula (sadness) and cingulate gyrus(emotions)
Symptoms: 2-years for adults; 1-year for children, deep depression with longer-lasting insomnia or hypersomnia and low self-esteem
Progression: little enjoyment in anything, suicidal behaviors, other disorders or addictions; hopelessness about life
Causes: genetic for 50% of cases; 75% have other physical illnesses, disorders or addictions; 95% have episodes of major depression.
Medications: antidepressants, but 6-8 weeks before progress; SSRIs, lithium
Therapies: cognitive therapy, better sleep, exercise
Youtube Video:
Life with Persistent Depressive Disorder (also known as Dysthymia)
Amazon or Library Book: Persistent Depressive Disorders
Click the book to link or order from Amazon.
Support Group: feelingkindablue.org; 866-728-7983
(Provident Behavioral Health)
Contact your local Social Security office for possible Disability Benefits through their Disability Determination Services,
Section 12.04
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic propertiesby Mazen A Atiq on May 14, 2024
Recent research with classic psychedelics suggests significant therapeutic potential, particularly for neuropsychiatric disorders. A mediating influence behind symptom resolution is thought to be the personal insight - at times, bordering on the mystical - one acquires during the acute phase of a psychedelic session. Indeed, current clinical trials have found strong correlations between the acute subjective effects (ASE) under the influence of psychedelics and their enduring therapeutic...
- Concentrated transdiagnostic and cross-disciplinary micro-choice based group treatment for patients with depression and with anxiety leads to lasting improvements after 12 months: a pilot studyby Ane Wilhelmsen-Langeland on May 14, 2024
CONCLUSIONS: The concentrated, micro-choice based group treatment approach yielded a highly clinically significant reduction in a wide range of symptoms already one week after treatment, and the positive results persisted at 12-month follow-up.
- Collaborative Care for Injured Older Adults: The Trauma Medical Home Randomized Clinical Trialby Ben L Zarzaur on May 8, 2024
CONCLUSIONS AND RELEVANCE: The TMH intervention did not significantly influence quality of life, depressive and anxiety symptoms, or physical function of older adults with injury at 12 months. Subgroup analysis showed positive impact in patients with a high burden of anxiety and depression symptoms at enrollment. Collaborative care interventions may improve long-term outcomes of select patients, but further research is needed.
- ER stress in mouse serotonin neurons triggers a depressive phenotype alleviated by ketamine targeting eIF2alpha signalingby Lluis Miquel-Rio on May 7, 2024
Depression is a devastating mood disorder that causes significant disability worldwide. Current knowledge of its pathophysiology remains modest and clear biological markers are lacking. Emerging evidence from human and animal models reveals persistent alterations in endoplasmic reticulum (ER) homeostasis, suggesting that ER stress-related signaling pathways may be targets for prevention and treatment. However, the neurobiological basis linking the pathways involved in depression-related ER...